Living Laboratory Partner MR CoilTech Secures Prestigious Grant for NEUROQUANT Project
Published: 21 January 2025
Living Laboratory partner MR CoilTech has secured a prestigious grant for its NEUROQUANT project, a pioneering study on Alzheimer’s disease that utilises the custom-built neurovascular coil developed as part of our Coil Development project.
Living Laboratory partner MR CoilTech has secured a prestigious grant for its NEUROQUANT project, a pioneering study on Alzheimer’s disease that utilises the custom-built neurovascular coil developed as part of our Coil Development project.
The two-year study is jointly funded by Innovate UK and InnoSuisse, and is being delivered by MR CoilTech in collaboration with UK-based Gold Standard Phantoms, and Skope Magnetic Resonance Technologies and Hopitaux Universitaires Geneve in Switzerland.
The NEUROQUANT project will harness the new neurovascular coil to enhance Alzheimer’s disease diagnosis, prognosis, and therapy monitoring. Given the global health challenge posed by Alzheimer’s, this study will play a key role in advancing diagnostic precision and improving patient outcomes.
The neurovascular coil is the second in a series of body-part-specific 7T MRI coils that are being constructed and validated with MR CoilTech as part of the Living Laboratory’s Coil Development project. A head coil has already been developed for clinical use, with pelvic and spinal imaging coils next in line.
The enhanced imaging power generated by these new coils will ultimately extend the utility of 7T MRI for diagnosing and monitoring a wide range of diseases, including Alzheimer’s.
The Living Laboratory looks forward to the NEUROQUANT project’s contributions to Alzheimer’s care, with the potential to positively impact millions of lives around the world.
First published: 21 January 2025
<< News
